Back

Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 7 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Robert Mentz

Duke University Medical Center, Durham (United States of America)

7 More presentations in this session

Presentation thumbnail
A prospective interventional randomized study to assess efficacy of angiotensin receptor neprilysin inhibitor in right ventricular systolic dysfunction with normal left ventricular systolic function.
Doctor R. Mathur (Jodhpur, IN)
Abstract Slides Video
Presentation thumbnail
Optimization of pharmacological treatment of heart failure in patients followed in specialized HF units in Spain.
Doctor R. Gonzalez-Manzanares (Cordoba, ES)
Abstract Slides Video
Presentation thumbnail
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.
Doctor R. Carvalho (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Characteristics of patients initiating dapagliflozin for heart failure with reduced ejection fraction in Italian clinical practice: a 6-month interim analysis of EVOLUTION-HF Italy
Associate Professor P. Ameri (Genova, IT)
Abstract Slides Video
Presentation thumbnail
Asymptomatic versus symptomatic hypotension in HFrEF: Findings with sacubitril/valsartan in PARADIGM-HF
Doctor S. Matsumoto (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 7

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Influence of ejection fraction on outcomes with sacubitril/valsartan in patients with worsening heart failure with EF>40%: the PARAGLIDE-HF Trial
thumbnail
Congress Presentation
Analysis of the PARAGON-HF study results using win ratio
thumbnail
Congress Presentation
Efficacy and safety of sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction according to background MRA therapy: a pooled analysis of PARAGLIDE-HF and PARAGON-HF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources